Posted inWire
Japan’s Astellas Pharma to acquire U.S. drugmaker Iveric Bio for $5.9 billion
Astellas Pharma, Japan's third-largest drugmaker by sales, has announced its biggest-ever acquisition with the purchase of US-based Iveric Bio for around $5.9 billion. The deal marks the company's fifth major…